Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.35 |
| ▸ | THPO | P40225 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | RGS12 | O14924 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11539994 | 0.85 | KDM4E (0.38) | KDM4ELMNAADRA2CHIF1AADRA2A | |
| SCHEMBL6839350 | 0.81 | KDM4E (0.46) | KDM4ELMNAADRA2CHIF1AADRA2A | |
| SCHEMBL9697406 | 0.79 | — | — | |
| SCHEMBL426212 | 0.79 | — | — | |
| SCHEMBL8133411 | 0.79 | ADRA2A (0.31) | KDM4ELMNAADRA2CHIF1AADRA2A | |
| SCHEMBL27482736 | 0.77 | — | — | |
| SCHEMBL28040600 | 0.77 | NOS3 (0.39) | KDM4ELMNAADRA2CHIF1AADRA2A | |
| SCHEMBL27293370 | 0.76 | KDM4E (0.50) | KDM4ELMNAADRA2CHIF1AADRA2A | |
| SCHEMBL8207275 | 0.75 | KDM4E (0.48) | KDM4ELMNAADRA2CHIF1AADRA2A | |
| SCHEMBL3762114 | 0.75 | ESR1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | claimed |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | claimed |
| US-8722726-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | claimed |
| EP-2118094-B1 | GAMMA-LACTAMS FOR THE TREATMENT OF GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2013-04-17 | — | — | EP | claimed |
| EP-2257548-B1 | THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2012-12-26 | — | — | EP | claimed |
| US-7956051-B2 | Therapeutic amides and related compounds | ALLERGAN, INC. (US) | 2011-06-07 | — | — | US | claimed |
| EP-2247583-A1 | HYDRAZINES IN GLAUCOMA THERAPY | ALLERGAN, INC. (US) | 2010-11-10 | — | — | EP | claimed |
| US-20100137347-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-06-03 | — | — | US | claimed |
| EP-2121609-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | Allergan, Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| WO-2009094286-A1 | HYDRAZINES IN GLAUCOMA THERAPY | ALLERGAN, INC. (US) | 2009-07-30 | — | — | WO | claimed |
| US-20090192151-A1 | THERAPEUTIC AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. | 2009-07-30 | — | — | US | claimed |
| WO-2008091818-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-07-31 | — | — | WO | claimed |
| CN-1312229-C | Process for producing chemically treated fillers | PPG IND OHIO INC (US) | 2007-04-25 | — | — | CN | claimed |
| CN-1312228-C | Process for producing chemically modified fillers | PPG IND OHIO INC (US) | 2007-04-25 | — | — | CN | claimed |
| CN-1374989-A | Process for producing chemically treated fillers | PPG IND OHIO INC (US) | 2002-10-16 | — | — | CN | claimed |
| CN-1374988-A | Process for producing chemically modified fillers | PPG IND OHIO INC (US) | 2002-10-16 | — | — | CN | claimed |
| CN-105520941-B | Substituted gamma lactams as therapeutic agents | 阿勒根公司 | 2020-05-01 | — | — | CN | disclosed |
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| CN-1374989-A | Process for producing chemically treated fillers | PPG IND OHIO INC (US) | 2002-10-16 | — | — | CN | disclosed |
| CN-1374988-A | Process for producing chemically modified fillers | PPG IND OHIO INC (US) | 2002-10-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | KDM4E 2381/4885LMNA 3131/4885ADRA2C 570/4885 |
| US-20090192151-A1 | THERAPEUTIC AMIDES AND RELATED COMPOUNDS | VIP, SHH, GLI1 | KDM4E 1468/4885LMNA 3937/4885ADRA2C 2246/4885 |
| US-20100137347-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | KDM4E 2953/4885LMNA 2522/4885ADRA2C 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.